MBQ-167 not checked

MBQ Pharma · Rac and Cdc42 inhibitor · Cdc42 inhibitor

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Breast Cancer, Breast Neoplasm, Breast Cancer Stage IV
Main trialPhase 1
“A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable.”In the company’s words, NCT06075810 on ClinicalTrials.gov
Other names
Rac and Cdc42 inhibitor · Rac inhibitor · Cdc42 inhibitor · PAK inhibitor · Rac/Cdc42 inhibitor

Other drugs for Breast Cancer

All 397 drugs for Breast Cancer

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Recruiting 31 Dec 2026 A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow MBQ-167

Following is part of Solo: you see every change to MBQ-167 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in